Capricor Therapeutics (CAPR) Misses Q2 EPS by 2c

Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.26), $0.02 worse than the analyst estimate of ($0.24).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• CVG to join Russell 2000 and Russell 3000 indexes June 26